Previous 10 | Next 10 |
Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NYSE American: MYO) ...
2023-11-06 17:35:58 ET Myomo ( NYSE: MYO ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, after market close. The consensus EPS Estimate is -$0.09 and the consensus Revenue Estimate is $4.15M (+4.5% Y/Y). Over the last 1 year, MYO has beaten E...
Public Meeting Scheduled for November 29, 2023 Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, t...
Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those su...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for th...
2023-09-22 12:52:13 ET For further details see: CETX, MYO and MORF among mid-day movers
2023-09-12 12:57:49 ET More on Myomo Seeking Alpha’s Quant Rating on Myomo Historical earnings data for Myomo Myomo: Game-Changing Medicare Reimbursement Should Create Lasting Value plans for stock offering, size not disclosed For further detai...
2023-09-12 12:52:44 ET Gainers: Anebulo Pharmaceuticals ( ANEB ) +35% . WeWork ( WE ) +34% . Shengfeng Development Limited ( SFWL ) +29% . AEON Biopharma ( AEON ) +28% . Avalo Therapeutics ( AVTX ) +28% . The Beauty Health Co...
2023-09-05 09:00:00 ET Summary CMS changed their policy to include Myomo's MyoPro devices as a covered product under Medicare. Proposed broad coverage would result in significant operating leverage and sustainable profitability for Myomo. Anemic valuation provides outsized ret...
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 17:00:05 ET Scott Henry from Industrial Alliance Securities issued a price target of $5.75 for MYO on 2024-07-10 15:33:00. The adjusted price target was set to $5.75. At the time of the announcement, MYO was trading at $4.97. The overall price target consensus...
2024-07-10 16:15:02 ET Alliance Global Partners analyst issues BUY recommendation for MYO on July 10, 2024 03:33PM ET. The previous analyst recommendation was Buy. MYO was trading at $4.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-09 10:30:11 ET Lake Street analyst issues BUY recommendation for MYO on July 9, 2024 08:45AM ET. The previous analyst recommendation was Buy. MYO was trading at $4.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...